PhRMA submits comments to Special 301 Report

The Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments this month to the 2017 Special 301 Report.
The comments home in on market access and intellectual property barriers in 18 countries and negatively affect biopharmaceutical innovators in the U.S., as well as individuals receiving medical care around the world.
The comments will be published in April by the U.S. Trade Representative (USTR), with whom PhRMA is urging to pay closer attention to the barriers that are facing the biopharmaceutical products -- tariffs, taxes, approval delays from overseas markets and more. 
American biopharmaceutical companies employ more than 850,000 individuals to develop and deliver new medications to the market. PhRMA is seeking competitive pricing of medicines, transparency in the reimbursement process and actions to counter the manufacture of counterfeit medications around the world.
The Special 301 Report is an annual publication that investigates topics of intellectual property protection and enforcement, both looking into the difficulties that the U.S. industries in the overseas markets are facing. The Report also considers ways that jobs can be created by patent, trademark and copyright protection.